Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Riccardo Puntoni is active.

Publication


Featured researches published by Riccardo Puntoni.


The Journal of Pathology | 2001

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

Luigi Strizzi; Alfonso Catalano; Giovina Vianale; Sara Orecchia; Angelo Casalini; Gianfranco Tassi; Riccardo Puntoni; L. Mutti; Antonio Procopio

Vascular endothelial growth factor (VEGF), a potent mitogen for vascular endothelium, is expressed in malignant pleural mesothelioma (MM). The present report examines the effect of VEGF on MM growth. Four MM cell lines produced significantly higher VEGF levels than normal mesothelial cells (1946±14 pg/ml vs. 180±17 pg/ml; p<0.001). In addition, MM cells expressed the tyrosine kinase‐related VEGF receptors Flt‐1 and KDR. Recombinant human VEGF phosphorylated both Flt‐1 and KDR and increased proliferation of all four MM cell lines in a dose‐dependent fashion. Neutralizing antibodies against either VEGF, Flt‐1 or KDR significantly reduced MM cellular proliferation. In addition, expression of VEGF, Flt‐1, and KDR was observed in MM biopsies. Moreover, higher VEGF levels were found in the pleural effusions of MM patients than in the effusions of patients with non‐malignant pleural disease (1885.7±894.9 pg/ml vs. 266.9±180.5 pg/ml; p<0.001). Linear regression analysis showed a significant inverse correlation between serum VEGF levels and MM patient survival (r=0.72; p<0.01). No correlation was found between tumour vessel density and either serum (r=0.26; p=0.42) or pleural effusion (r=0.35; p=0.26) VEGF levels. These results indicate that VEGF, via activation of its tyrosine kinase receptors, may be a key regulator of MM growth. In addition, VEGF production could have an impact on patient survival, not only by promoting tumour angiogenesis but also by directly stimulating tumour growth. Copyright


Cancer Genetics and Cytogenetics | 1995

Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study

Stefano Bonassi; Angelo Abbondandolo; Lamberto Camurri; Leda Dal Prá; Marcella De Ferrari; Francesca Degrassi; Alessandra Forni; Laura Lamberti; Cecilia Lando; Paola Padovani; Isabella Sbrana; Daniela Vecchio; Riccardo Puntoni

To investigate the existence of an association between the frequency of chromosome aberrations (CA) in non-target tissues and cancer risk, a historical cohort study was carried out in a group of 1455 subjects screened for CA over the last 20 years in Italy. Statistically significant increases in standardized mortality ratio (SMR) for all cancers were found in subjects with medium and high levels of CA in peripheral blood lymphocytes (SMR = 178.5 and SMR = 182.0, respectively) and in subjects with high levels of CA for respiratory tract cancers (SMR = 250.8) and lymphatic and hematopoietic tissue neoplasms (SMR = 548.8). Significant trends in the SMRs were observed for these latter causes of death.


Cancer Research | 2006

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

Ramasamy Jagadeeswaran; Patrick C. Ma; Tanguy Y. Seiwert; Sujatha Jagadeeswaran; Osvaldo Zumba; Vidya Nallasura; Salman Ahmed; Rosangela Filiberti; Michela Paganuzzi; Riccardo Puntoni; Robert A. Kratzke; Gavin J. Gordon; David J. Sugarbaker; Raphael Bueno; Varalakshmi Janamanchi; Vytas P. Bindokas; Hedy L. Kindler; Ravi Salgia

c-Met receptor tyrosine kinase (RTK) has not been extensively studied in malignant pleural mesothelioma (MPM). In this study, c-Met was overexpressed and activated in most of the mesothelioma cell lines tested. Expression in MPM tissues by immunohistochemistry was increased (82%) in MPM in general compared with normal. c-Met was internalized with its ligand hepatocyte growth factor (HGF) in H28 MPM cells, with robust expression of c-Met. Serum circulating HGF was twice as high in mesothelioma patients as in healthy controls. There was a differential growth response and activation of AKT and extracellular signal-regulated kinase 1/2 in response to HGF for the various cell lines. Dose-dependent inhibition (IC50 < 2.5 micromol/L) of cell growth in mesothelioma cell lines, but not in H2052, H2452, and nonmalignant MeT-5A (IC50 > 10 micromol/L), was observed with the small-molecule c-Met inhibitor SU11274. Furthermore, migration of H28 cells was blocked with both SU11274 and c-Met small interfering RNA. Abrogation of HGF-induced c-Met and downstream signaling was seen in mesothelioma cells. Of the 43 MPM tissues and 7 cell lines, we have identified mutations within the semaphorin domain (N375S, M431V, and N454I), the juxtamembrane domain (T1010I and G1085X), and an alternative spliced product with deletion of the exon 10 of c-Met in some of the samples. Interestingly, we observed that the cell lines H513 and H2596 harboring the T1010I mutation exhibited the most dramatic reduction of cell growth with SU11274 when compared with wild-type H28 and nonmalignant MeT-5A cells. Ultimately, c-Met would be an important target for therapy against MPM.


Clinical Cancer Research | 2007

Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer

Alfonso Cristaudo; Rudy Foddis; Agnese Vivaldi; Giovanni Guglielmi; Nicola Dipalma; Rosangela Filiberti; Monica Neri; Marcello Ceppi; Michela Paganuzzi; Gian Paolo Ivaldi; Manlio Mencoboni; Pier Aldo Canessa; Nicolino Ambrosino; Antonio Chella; Luciano Mutti; Riccardo Puntoni

Purpose: High levels of serum-soluble mesothelin family proteins (SMRP) have been found to be associated with malignant mesothelioma (MM), but not lung cancer (LC). To verify the clinical role of this marker for both these tumors, we tested serum SMRP in the largest population of thoracic cancers ever assembled. Experimental Design: SMRP blood concentrations were measured in 107 patients with MM, 215 patients with LC, 130 patients with benign respiratory diseases (BRD), and 262 controls. Statistical comparison between mean serum SMRP levels in all groups was done and receiver operating characteristic curves were constructed to evaluate the performance of this marker. Results: SMRP levels were significantly higher in patients with MM and LC than in patients with benign respiratory diseases and controls (P < 0.001). The area under the receiver operating characteristic curve for serum SMRP discriminating MM and controls was 0.77 (95% confidence interval, 0.71-0.83), with a best cutoff of 1.00 nmol/L (sensitivity, 68.2%; specificity, 80.5%). In both MM and LC, serum SMRP levels did not differ significantly between early and late stages. High SMRP levels proved to be an independent negative prognostic factor in patients with MM. Conclusions: Our data confirm that serum SMRP is a promising marker for the diagnosis, prognosis, and clinical monitoring of MM. We found that serum SMRP dosage may prove helpful in LC diagnosis as well. These data may also have positive repercussions on secondary preventive medical strategies for workers previously exposed to asbestos.


British Journal of Cancer | 1992

A case-control study of cancers of the gastric cardia in Italy

Domenico Palli; Simonetta Bianchi; A. Decarli; Francesco Cipriani; Claudio Avellini; Pierluigi Cocco; Fabio Falcini; Riccardo Puntoni; Antonio Russo; Carla Vindigni

In a case-control study of gastric cancer (GC) in high-risk and low-risk areas in Italy, 923 GCs were reviewed by one pathologist and classified according to anatomic site. There were 68 (7.4%) cancers occurring in the gastric cardia. Compared to other GCs, cardia cancer tended to occur more often in males (sex ratio 2.8 vs 1.7) and as intestinal or unclassified histologic types. Nutritional factors for cardia tumours resembled those of other GCs, showing inverse associations with the consumption of raw vegetables, citrus and other fresh fruit, and ascorbic acid, and positive associations with the intake of traditional soups and meat, protein and cholesterol, and preference for salty foods. Cigarette smoking and wine consumption were unrelated to cardia cancer risk, and there was only a weak association with total alcohol intake. Cardia tumours showed a greater familial occurrence of GC than did other sites, with a 7-fold increase in risk for those reporting two first-degree relatives with GC. The authors discuss these findings in view of the rising incidence of adenocarcinomas of the cardia and lower oesophagus that has been reported in some western countries.


Mutation Research | 2001

Validation of biomarkers as early predictors of disease.

Stefano Bonassi; Monica Neri; Riccardo Puntoni

The development and validation of biomarkers that link environmental exposures to the pathogenesis of human disease is a leading priority in the field of environmental research. The validation of biomarkers as early predictors of clinical disease can enhance health risk assessment and contribute to effective new disease prevention policies in environmental and occupational settings. The process of validating biomarkers involves dealing with a range of characteristics that include the intrinsic qualities of the biomarker, its determinants, and the analytic procedure. We discuss here a three phase approach to validation. The final phase, consisting of longitudinal studies, is reached after the biomarker has been determined to be technically reliable and after the effect of external variables on the association with the outcome has been evaluated. We provide some examples of biomarkers reputed to be early predictors of cancer and cardiovascular disease (CVD). We then present original data to support the potential of DNA adducts to predict cancer and show, through re-evaluation of the Italian database on cytogenetic biomarkers, a lack of association between the frequency of chromosomal aberrations in circulating lymphocytes and CVD mortality rates -- a finding that should not be considered conclusive. In general, whenever a biomarker has been determined to be a valid predictor of disease, it should be used in risk assessment and public health policy.


Cancer Research | 2005

SV40 Enhances the Risk of Malignant Mesothelioma among People Exposed to Asbestos: A Molecular Epidemiologic Case-Control Study

Alfonso Cristaudo; Rudy Foddis; Agnese Vivaldi; R Buselli; V. Gattini; Giovanni Guglielmi; Francesca Cosentino; Franco Ottenga; Eugenio Ciancia; Roberta Libener; Rosangela Filiberti; Monica Neri; PierGiacoino Betta; Mauro Tognon; Luciano Mutti; Riccardo Puntoni

We conducted a case-control study on asbestos exposure and presence of SV40 in tumor samples of malignant mesotheliomas (MMs) and bladder urotheliomas (BUs). PCR analysis revealed the presence of SV40 DNA (SV40+) in eight (42.1%) MMs and 6 (33.3%) BUs. The odds ratio for MM Asb- and SV40+ was 0.4 [95% confidence interval (95% CI), 0.03-4.0], for Asb+ and SV40- was 3.6 (95% CI, 0.6-21.0), and for Asb+ and SV40+ was 12.6 (95% CI, 1.2-133.9). Our results suggest that SV40 increases the risk of MM among individuals exposed to asbestos.


Annals of the New York Academy of Sciences | 1979

MORTALITY AMONG SHIPYARD WORKERS IN GENOA, ITALY

Riccardo Puntoni; Marina Vercelli; Franco Merlo; Federico Valeric; Leonardo Santi

The dockyards of Genoa are exposed to many known or suspect carcinogenic agents, namely, asbestos, silica, polycyclic aromatic hydrocarbons, and halogenated hydrocarbons; other possibly harmful substances are trace amounts of aromatic amines, welding smokes, paints, and lipid-removing solvents. A cohort study of causes of death of 2190 dockyard workers in Genoa was conducted between January 1, 1960 and December 31, 1975. Mortality rates were calculated for 20 different occupational categories, for which there exist different levels of exposure to noxious substances. Two control groups were selected: the general male population of Genoa and all male employees (462) of San Martino Hospital, Genoa for the same period of time. Causes of death that demonstrated significant excesses for both control groups were: cancer of the colon, excluding the rectum; cancer of the larynx; cancer of the lung, bronchus, and trachea; cancer of the kidney, urinary bladder, and other urinary organs; respiratory diseases; and cirrhosis of the liver. The data obtained from these 20 job categories revealed different types and levels of risk for various carcinogenic agents.


Environmental Health Perspectives | 2005

Baseline Micronuclei Frequency in Children: Estimates from Meta- and Pooled Analyses

Monica Neri; Marcello Ceppi; Lisbeth E. Knudsen; Domenico Franco Merlo; Roberto Barale; Riccardo Puntoni; Stefano Bonassi

The number of studies evaluating the effect of environmental exposure to genotoxic agents in children has rapidly increased in the last few years. The frequency of micronuclei (MN) in peripheral blood lymphocytes determined with the cytokinesis block assay is among the most popular biomarkers used for this purpose, although large inter- and intralaboratory variability of this end point has been observed in population studies. The availability of reference measures is therefore necessary for laboratories to validate protocols and analytical procedures, and for molecular epidemiologists, as well, to estimate the statistical power of studies and to assess the quality of data. In this article, we provide estimates of the baseline frequency of MN in children, conducting a meta-analysis of MN frequency reported by field studies in children and a pooled analysis of individual data [available from published studies and from the Human Micronucleus International Collaborative Study (HUMN) database]. Thirteen articles were selected for meta-analysis, and individual data included in the pooled analysis were retrieved from the databases of 12 laboratories. Overall means of 4.48 [95% confidence interval (CI), 3.35–5.98] and 5.70 (95% CI, 4.29–7.56) MN per 1,000 binucleated cells were estimated by the meta- and pooled analysis, respectively. A clear effect of age was detected, even within the restricted range of pediatric age considered, with significantly lower frequency values in newborns. No influence of sex was found. The study showed the advantage of using data from large collaborative studies and suggested a synergistic use of meta- and pooled analysis.


Cancer Research | 2009

Estrogen Receptor-β Affects the Prognosis of Human Malignant Mesothelioma

Giulia Pinton; Elisa Brunelli; Bruno Murer; Riccardo Puntoni; Matteo Puntoni; Dean A. Fennell; Giovanni Gaudino; Luciano Mutti; Laura Moro

Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase in the next decades. Female gender was identified as a positive prognostic factor among other clinical and biological prognostic markers for malignant mesothelioma, yet a role of estrogen receptors (ERs) has not been studied. Our goal was to investigate ERs expression in malignant mesothelioma and to assess whether their expression correlates with prognosis. Immunohistochemical analysis revealed intense nuclear ERbeta staining in normal pleura that was reduced in tumor tissues. Conversely, neither tumors nor normal pleura stained positive for ERalpha. Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival. Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation. Consistently cell growth was suppressed by ERbeta overexpression, causing a G(2)-M-phase cell cycle arrest, paralleled by cyclin B1 and survivin down-regulation. Our data support the notion that ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression and to therapeutic response of malignant mesothelioma patients.

Collaboration


Dive into the Riccardo Puntoni's collaboration.

Top Co-Authors

Avatar

Monica Neri

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Rosangela Filiberti

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Stefano Bonassi

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Marcello Ceppi

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Franco Merlo

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vincenzo Fontana

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Michela Paganuzzi

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Paola Marroni

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge